Neurology & Neurological Sciences

Pediatric Neuro-Oncology Clinical Trials

LOW GRADE GLIOMA (LGG)

Newly Diagnosed

ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND #77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Diagnosis: Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Diagnosis: Low-Grade Glioma (LGG)

Recurrent/Refractory/Progressive

DIPG

Newly Diagnosed

PBTC060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Diagnosis: Diffuse Intrinsic Pontine Glioma (DIPG)

PBTC048: Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Diagnosis: Diffuse Intrinsic Pontine Glioma (DIPG)

GD2 CAR-T: Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
Diagnosis: Diffuse Intrinsic Pontine Glioma (DIPG) and Spinal Cord Diffuse Midline Glioma (DMG) that is H3K27 mutated

Recurrent/Refractory/Progressive

HIGH GRADE GLIOMA (HGG)

Newly Diagnosed

ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Diagnosis: High-Grade Glioma (HGG)

Eli Lilly: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Diagnosis: High-Grade Glioma (HGG)

Recurrent/Refractory/Progressive

PBTC060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Diagnosis: High Grade Glioma (HGG)

PBTC048: A Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Diagnosis: Supratentorial HGG

PBTC-049: A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors
Diagnosis: Recurrent, progressive, or refractory primary CNS tumor with evidence of genetic activation of the MET pathway

A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Diagnosis: High Grade Glioma (HGG)

EPENDYMOMA

Newly Diagnosed

Recurrent/Refractory/Progressive

PBTC060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Diagnosis: Ependymoma

PBTC048: A Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Diagnosis: Supratentorial ependymoma

MEDULLOBLASTOMA

Newly Diagnosed

Recurrent/Refractory/Progressive

PBTC060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Diagnosis: Medulloblastoma

PBTC-049: A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors
Diagnosis: Recurrent, progressive, or refractory primary CNS tumor with evidence of genetic activation of the MET pathway

PBTC-053: Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma
Diagnosis: Recurrent SHH Medulloblastoma

ATYPICAL TERATOID RHABDOID TUMOR (ATRT)

Newly Diagnosed

Recurrent/Refractory/Progressive

NEUROFIBROMATOSIS-1 (NF1)

Newly Diagnosed

Recurrent/Refractory/Progressive

Other - nontreatment

OTHER & MOLECULAR BASED THERAPIES

Other & Molecular Based Therapies

ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Diagnosis: Newly diagnosed germinoma

ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Diagnosis: Newly diagnosed with localized primary CNS NGGCT of the suprasellar and/or pineal region

ACCL2031: A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Diagnosis: Primary Central Nervous System Tumors

G042286: A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
Diagnosis: CNS or solid tumors harboring ALK gene fusions

APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility, Screening, Biology, and Outcome Study
Diagnosis: Registry or eligibility arm

PBTC-N14: CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients with Primary Brain Tumors
Diagnosis: Primary Central Nervous System Tumors

FURTHER INFORMATION AND SUMMARIES FOR HEALTH CARE PROFESSIONALS

Further Information and Summaries for Health Care Professionals

For more information

To find out the current status of any study please contact us at:

Merkel@stanford.edu

jmaala@stanford.edu